论文信息 - Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION NCT01751568.

[1] H. Teppler,et al. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. , 2019, AIDS.

[2] A. Turkova,et al. Treating young children co-infected with tuberculosis and HIV. , 2019, The lancet. HIV.

[3] Jingtao Gao,et al. Guidelines for treatment of drug-susceptible tuberculosis and patient care-2017 update , 2018 .

[4] P. Denti,et al. Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. , 2019, The lancet. HIV.

[5] C. Rouzioux,et al. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship , 2014, The Journal of antimicrobial chemotherapy.

[6] J. Chodakewitz,et al. Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir , 2009, Antimicrobial Agents and Chemotherapy.

[7] G. Maartens,et al. Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis , 2009, Journal of acquired immune deficiency syndromes.